Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: Recent cardiovascular outcome trials have shown that sodium–glucose co-transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes at high cardiovascular risk. Whether these benefits extend to CKD patients without type 2 diabetes or cardiovascular disease is unknown. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial (NCT03036150) will assess the effect of the SGLT2 inhibitor dapagliflozin on renal and cardiovascular events in a broad range of patients with CKD with and without diabetes. Methods: DAPA-CKD is a randomized, double-blind, placebo-controlled, trial in which ∼4300 patients with CKD Stages 2–4 and elevated urinary albumin excretion will be enrolled. The vast majority will be receiving a maximum tolerated dose of a renin–angiotensin system inhibitor at enrolment. Results: After a screening assessment, eligible patients with a urinary albumin:creatinine ratio ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 are randomly assigned to placebo or dapagliflozin 10 mg/day. Enrolment is monitored to ensure that at least 30% of patients do not have diabetes and that no more than 10% have an eGFR >60 mL/min/1.73 m2. The primary endpoint is a composite of a sustained decline in eGFR of ≥50%, end-stage renal disease, renal death or cardiovascular death. The trial will conclude when 681 primary renal events have occurred, providing 90% power to detect a 22% relative risk reduction (α level of 0.05). Conclusion: DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 4×
“An unexpected increase in the rate of lower limb amputation was reported with canagliflozin in the CANVAS Program but not in the CREDENCE trial.[3, 5] This has not been observed with dapagliflozin in any prior study, including DECLARE TIMI-58 and DAPA-Heart Failure”
BackgroundResultInfluentialDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 3×
“due to renal or cardiovascular disease) by 30% compared to placebo.[5] In the cardiovascular and renal outcome trials described above, the reno-protective benefits of the SGLT2 inhibitors did not appear to be completely explained by the modest reductions in HbA1c, which are attenuated in patients with a low eGFR.”
BackgroundResultSelf-citationHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationPerkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.251 · Cited by 350
Lundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108
Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx350 · Cited by 102
Self-citationJobori, H. A., Daniele, G., Adams, J. M., Cersósimo, E., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12881 · Cited by 86
Cited by
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationKalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationPalmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556
Self-citationWheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
“primary or secondary kidney disease within the previous 6 months before trial enrollment.(16,17)”
BackgroundInfluentialSelf-citationJhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050391 · Cited by 307
Self-citationCherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30162-5 · Cited by 283
Self-citationEffects of dapagliflozin in stage 4 chronic kidney disease
Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021020167 · Cited by 201
Self-citationHonigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127
Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa294 · Cited by 103
Self-citationHeerspink, H. J. L., Oshima, M., Zhang, H., Li, J., Agarwal, R., Capuano, G., Charytan, D. M., Craig, J., de Zeeuw, D., Di Tanna, G. L., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.005 · Cited by 56
Self-citationReifsnider, O. S., Kansal, A. R., Wanner, C., Pfarr, E., Koitka-Weber, A., Brand, S. B., Stargardter, M., Wang, C., Kuti, E., & Ustyugova, A. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.014 · Cited by 52
McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14308 · Cited by 34
Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23
Beernink, J. M., Persson, F., Jongs, N., Laverman, G. D., Chertow, G. M., McMurray, J. J. V., Langkilde, A. M., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1514 · Cited by 18
“Outcomes As described previously (10), the primary clinical trial end point was a composite of sustained $50% decline in the eGFR (confirmed by a second measurement after at least 28 days), onset of end-stage kidney disease (defined as maintenance dialysis for >28 days, kidney transplantation, or eGFR <15 mL/min/1.”
BackgroundSelf-citationKim, C. H., Hwang, I.-C., Choi, H.-M., Ahn, C. H., Yoon, Y. E., & Cho, G.-Y. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.027 · Cited by 16
Metadata
- Authors
- Heerspink, H. J. L., Stefansson, B. V., Chertow, G. M., Correa-Rotter, R., Greene, T., Hou, F.-F., Lindberg, M., McMurray, J., Rossing, P., Toto, R., Langkilde, A. M., Wheeler, D. C., for the DAPA-CKD Investigators, Heerspink, H. J. L., Wheeler, D. C., Chertow, G., Correa-Rotter, R., Greene, T., Hou, F.-F., McMurray, J., Rossing, P., Toto, R., Stefansson, B., Langkilde, A. M., Pfeffer, M. A., Pocock, S., Swedberg, K., Rouleau, J. L., Chaturvedi, N., Ivanovich, P., Levey, A. S., Christ-Schmidt, H., Mann, J., Held, C., Varenhorst, C., Holmgren, P., Hallberg, T., Douthat, W., Filho, R. P., Cherney, D., Hou, F. F., Persson, F., Haller, H., Wittmann, I., Tudományegyetem, P., Khullar, D., Naoki, K., Correa-Rotter, R., Escudero, E., Isidto, R., Iloilo, H., Nowicki, M., Batiushin, M., Kang, S.-W., Teruel, J. L. G., Furuland, H., Bilchenko, O., Mark, P., Dwyer, J., & Van Bui, P.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-02-01
- Volume
- 35
- Issue
- 2
- Pages
- 274-282
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W3005350465
- Cited by
- 218
- References
- 13
- FWCI
- 26.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- AstraZeneca
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.